时间：2022年7月15日（周五） 16:00-17:30

Time: 16:00-17:30, Friday, July 15, 2022

线上：ZOOM ID 826 5574 6191

Online: ZOOM ID 826 5574 6191

主持人: 西湖大学工学院 程建军博士

Host: Dr.Jianjun Cheng, Chair Professor, Westlake University

主讲嘉宾/Speaker：

Prof. Jun Wang 王均

School of Biomedical Science and Engineering

South China University of Technology

主讲人简介/Biography:

From 1999-2002, Jun Wang got postdoctoral training at Tissue and Therapeutic Engineering Lab, Johns Hopkins in Singapore. Then, from 2002-2004, he worked as a postdoctoral fellow at the Department of Biomedical Engineering, Johns Hopkins University School of Medicine. From 2002-2004, he worked as a professor at the University of Science and Technology of China (USTC). In June 2016, he moved to SCUT, as a professor of Institutes for Life Sciences and School of Medicine, and as a researcher of the National Engineering Research Centre for Tissue Restoration and Reconstruction. Since December 2017, he has been assigned as Dean of the School of Biomedical Sciences and Engineering, SCUT. Prof. Wang has been engaged in the teaching and scientific research of biomedical materials and nanomedicine for many years and has published more than 180 peer-reviewed scientific papers in Sci. Transl. Med., Nat. Commun., PNAS、J. Am. Chem. Soc. and other journals, which have been cited over 20000 times.

讲座摘要/Abstract:

Monoclonal antibodies (mAbs), represented by immune checkpoint inhibitors (ICIs), are currently the most widely used immunotherapeutic agents for tumor treatment. Unfortunately, a significant fraction of patients has not responded to ICIs treatment. In recent years, bi/multi-specific antibodies, which can recognize two or more two different epitopes (or antigens) and can potentially enhance the interaction between effector immune cells and tumor cells, are becoming a new hotspot in the field of antibody-drug development and are considered as the next-generation antibody-based therapeutics. However, the design, production, and purification of bi/multi-specific antibodies are considerably more challenging than that of conventional mAbs. Previously, we built up a versatile antibody immobilization platform (referred to as nano-adaptor) by engineering anti-IgG (Fc specific) antibody (αFc) onto nanoparticle surface and we confirmed that nano-adaptor could conveniently and efficiently immobilize one or more types of mAbs after gently mixing without compromising the antigen-binding capabilities of parental mAbs. More importantly, bi/multi-specific nano-antibodies demonstrate extremely efficient anti-tumor effects. To address the biosafety and scale-up preparation issues of the nano-adaptors, and to accelerate their clinical translation, we constructed a fusion protein-based composite nano-adaptor using FcγRI (Fc gamma receptor I)-albumin fusion protein and biomedical polymer materials. We are now focusing on the scale-up of the composite nano-adaptor, with preclinical trials imminent.

讲座联系人/Contact:

工学院石怀玮

shihuaiwei@westlake.edu.cn